Robin Hamilton
Overview
Explore the profile of Robin Hamilton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
876
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bhatia B, Sim S, Chalkiadaki E, Koutsocheras G, Nicholson L, Selvam S, et al.
Ophthalmol Ther
. 2025 Feb;
PMID: 40016538
Introduction: In clinical practice, intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection intervals for patients with neovascular age-related macular degeneration (nAMD) are based on disease activity, with active or recurrent disease...
2.
Li T, Berdunov V, Hamilton R, Rojas Y, Buhrer C, Cox O, et al.
Ophthalmol Ther
. 2024 Aug;
13(10):2577-2597.
PMID: 39106031
Introduction: Cost-effectiveness analyses typically ignore healthcare system resource constraints. Ophthalmology is affected by resource constraints because of increasing disease prevalence and the use of resource-intensive treatments. This study evaluated the...
3.
Sim S, Chalkiadaki E, Koutsocheras G, Nicholson L, Sivaprasad S, Patel P, et al.
Ophthalmol Retina
. 2024 Jul;
9(1):22-30.
PMID: 39084554
Purpose: To report 1-year anatomic and functional real-world outcomes of patients with treatment-intensive neovascular age-related macular degeneration (nAMD) switched to faricimab. Design: Retrospective multicenter cohort study. Subjects: Consecutive nAMD patients...
4.
Faes L, Mishra A, Lipkova V, Balaskas K, Quek C, Hamilton R, et al.
J Clin Med
. 2023 Jun;
12(12).
PMID: 37373573
Importance: Diabetic macular edema (DME) is a major cause of vision loss in patients with diabetes mellitus. Intravitreal dexamethasone is a treatment option for patients unsuitable for or non-responsive to...
5.
Woronkowicz M, Hamilton R, Lightman S, Zagora S, Tomkins-Netzer O
Int Ophthalmol
. 2023 Jun;
43(10):3499-3507.
PMID: 37318668
Purpose: To compare results of treatment with bevacizumab and ranibizumab injections in myopic choroidal neovascularization (mCNV). Methods: Retrospective, observational case series. Participants: patients with mCNV treated with bevacizumab or ranibizumab...
6.
Chorev M, Haderlein J, Chandra S, Menon G, Burton B, Pearce I, et al.
J Clin Med
. 2023 Apr;
12(8).
PMID: 37109349
Patients diagnosed with exudative neovascular age-related macular degeneration are commonly treated with anti-vascular endothelial growth factor (anti-VEGF) agents. However, response to treatment is heterogeneous, without a clinical explanation. Predicting suboptimal...
7.
Shalchi Z, Angunawela R, Hamilton R
J Curr Ophthalmol
. 2023 Jan;
34(3):384.
PMID: 36644455
No abstract available.
8.
Lois N, Campbell C, Waugh N, Azuara-Blanco A, Maredza M, Mistry H, et al.
Health Technol Assess
. 2022 Dec;
26(50):1-86.
PMID: 36541393
Background: The National Institute for Health and Care Excellence recommends macular laser to treat diabetic macular oedema with a central retinal subfield thickness of < 400 µm on optical coherence...
9.
Lois N, Campbell C, Waugh N, Azuara-Blanco A, Maredza M, Mistry H, et al.
Ophthalmology
. 2022 Aug;
130(1):14-27.
PMID: 35973593
Purpose: To determine clinical effectiveness, safety, and cost-effectiveness of subthreshold micropulse laser (SML), compared with standard laser (SL), for diabetic macular edema (DME) with central retinal thickness (CRT) < 400...
10.
Regillo C, Singh R, Hamilton R, Gedif K, Best C, Koh A, et al.
Ophthalmologica
. 2022 Apr;
245(5):403-412.
PMID: 35468601
Introduction: Neovascular age-related macular degeneration (nAMD) is characterized by exudation of fluid from abnormally growing blood vessels in the macula. Anti-vascular endothelial growth factor (VEGF) therapy is standard treatment for...